Konstantinos Xynos - Dec 1, 2022 Form 3 Insider Report for Replimune Group, Inc. (REPL)

Role
Chief Medical Officer
Signature
/s/ Jean Franchi, as attorney-in-fact
Stock symbol
REPL
Transactions as of
Dec 1, 2022
Transactions value $
$0
Form type
3
Date filed
12/5/2022, 07:00 PM
Next filing
Apr 4, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
holding REPL Common Stock 37.5K Dec 1, 2022 Direct F1
holding REPL Common Stock 7K Dec 1, 2022 Direct F2
holding REPL Common Stock 8.8K Dec 1, 2022 Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding REPL Employee Stock Option (right to buy) Dec 1, 2022 Common Stock 75K $28.62 Direct F3
holding REPL Employee Stock Option (right to buy) Dec 1, 2022 Common Stock 10.5K $18.26 Direct F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents shares of the Issuer's common stock issuable upon settlement of restricted stock units ("RSUs") granted to the Reporting Person. Each RSU represents a contingent right to receive one share of the Issuer's common stock. The Reporting Person was granted 50,000 RSUs on November 29, 2021, 25% of such RSUs vested and were released on November 15, 2022, and the remainder will vest in three approximately equal annual installments thereafter until November 15, 2025, subject to the Reporting Person's continuous service to the Issuer.
F2 Represents shares of the Issuer's common stock issuable upon settlement of RSUs granted to the Reporting Person. Each RSU represents a contingent right to receive one share of the Issuer's common stock. The Reporting Person was granted 7,000 RSUs on April 1, 2022, 25% of such RSUs vest on May 15, 2023, and the remainder will vest in three approximately equal annual installments thereafter until May 15, 2026, subject to the Reporting Person's continuous service to the Issuer.
F3 25% of the shares underlying this stock option vested on November 29, 2022, and the remainder of the shares underlying this stock option vest in 36 approximately equal monthly installments thereafter.
F4 25% of the shares underlying this stock option vest on April 1, 2023, and the remainder of the shares underlying this stock option vest in 36 approximately equal monthly installments thereafter.

Remarks:

Exhibit 24 - Power of Attorney